指南与共识关节外科

全关节置换术前停用激素替代治疗以降低术后血栓栓塞事件风险:是否合理?——临床实践指南的系统综述

Withholding of Hormone Replacement Therapy Prior to Total Joint Arthroplasty Surgery to Reduce the Risk of Postoperative Thromboembolic Events: Is It Justified?-A Systematic Review of Clinical Practice Guidelines.
指南 / 共识 · J Arthroplasty · 2023-08-26

该系统综述检索了2000年1月至2023年2月发表的7部来自欧洲和北美的英文国际临床实践指南,评估其关于择期下肢关节置换术前停用激素替代治疗(HRT)或绝经激素治疗(MHT)的一致性。指南意见不一,部分提供详细围手术期管理建议,部分无相关指导;所引证据多来自20世纪90年代和21世纪初,显示HRT或MHT增加静脉血栓栓塞(VTE)风险的作用有限。作者结论认为,基于当前证据,非含雌激素的经皮HRT或MHT不应在择期关节置换患者中停用,但停用含雌激素剂型仍需进一步证据。

要点

  • 7部国际指南对HRT或MHT停用意见不一,部分有详细建议,部分无指导。
  • 指南引用的证据多来自1990年代和2000年代,显示HRT或MHT增加VTE风险的作用有限。
  • 作者结论:非含雌激素的经皮HRT或MHT不应停用,含雌激素剂型停用仍需进一步证据。

核心结论

  • 基于当前证据,非含雌激素的经皮HRT或MHT在接受择期关节置换的患者中不应停用,但停用含雌激素剂型仍需进一步证据。

研究设计与样本

  • 系统综述,检索PubMed、Google Scholar、Cochrane和Ovid数据库及互联网,纳入2000年1月至2023年2月发表的7部来自欧洲和北美的英文国际临床实践指南,依据AGREE-II标准并按PRISMA清单进行评价。

主要发现

  • 所评价的指南对HRT或MHT在关节置换术中的停用与使用意见不一,部分指南(苏格兰校际指南网络)提供详细的术前和术后管理建议,而其他指南(美国胸科医师学会)无相关指导。
  • 指南引用的证据显示HRT或MHT在增加VTE风险中作用有限,多数研究来自1990年代和2000年代。

关键数值与推荐

  • 共评价7部国际英文临床实践指南,发表于2000年1月至2023年2月,来自欧洲和北美,依据AGREE-II标准评价。

临床怎么用

  • 作者结论认为,基于当前证据,非含雌激素的经皮HRT或MHT在接受择期关节置换的患者中不应停用,但停用含雌激素剂型仍需进一步证据。

局限性

  • 需要进一步证据来论证停用含雌激素剂型的合理性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hormone replacement therapy (HRT), menopausal hormone therapy (MHT), and estrogen-containing medications are frequently withheld before elective lower limb arthroplasty, based on a perceived risk of venous thromboembolism (VTE). However, evidence linking HRT, MHT, and an increased VTE risk is equivocal. This systematic review evaluated the concordance of international clinical practice guidelines (CPGs) on the withholding of HRT or MHT. METHODS: The PubMed, Google Scholar, Cochrane, and Ovid databases were searched for CPGs for the preoperative, perioperative, and postoperative management of patients on HRT and MHT undergoing elective lower limb arthroplasty. This was supplemented by an internet search. There were 7 international CPGs in English, from Europe and North America, published between January 2000 and February 2023 reviewed against the Appraisal of Guidelines for Research & Evaluation Instrument (AGREE-II) criteria, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist. RESULTS: The guidelines reviewed revealed a mixed picture on HRT or MHT withdrawal and use in arthroplasty, with some featuring detailed advice on the preoperative and postoperative management of HRT or MHT (Scottish Intercollegiate Guidelines Network), while others featured no guidance (American College of Chest Physicians). The evidence referenced in these guidelines highlighted studies showing HRT or MHT to play a limited role in increasing VTE risk, with most studies from the 1990s and 2000s. CONCLUSIONS: Based on current evidence, non-estrogen-containing transdermal HRT or MHT should not be withheld in patients undergoing elective joint arthroplasty, though further evidence is required to justify withholding estrogen-containing forms.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Abouharb ALZ, Mehta S, Rathnayake H, et al. Withholding of Hormone Replacement Therapy Prior to Total Joint Arthroplasty Surgery to Reduce the Risk of Postoperative Thromboembolic Events: Is It Justified?-A Systematic Review of Clinical Practice Guidelines. J Arthroplasty. 2023. PMID: 37634878. doi:10.1016/j.arth.2023.08.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。